Austrian Biotech Efferon Secures €2.5M Seed Funding to Expand Sepsis Treatment Manufacturing Across Europe
Efferon, a biotech company developing hemoadsorption devices for treating sepsis and septic shock, has secured €2.5 million in seed funding led by private investors from the DACH region. The company will use funds to build a new EU production facility and expand manufacturing capacity. Efferon’s products include Efferon LPS for general use and Efferon NEO for pediatric patients, with the latter recently receiving CE MDR certification. The technology has been used in over 25,000 treatments across 40+ countries.